Diabetes 56:1856-1864, 2007 DOI: 10.2337/db06-1065 © 2007 by the American Diabetes Association
Tissue-Specific Effects of Rosiglitazone and Exercise in the Treatment of Lipid-Induced Insulin Resistance
1 School of Medical Sciences, RMIT University, Bundoora, Victoria, Australia Address correspondence and reprint requests to John A. Hawley, School of Medical Sciences, RMIT University, P.O. Box 71, Bundoora, Victoria 3083, Australia. E-mail: john.hawley{at}rmit.edu.au
Abbreviations:
ACC, acetyl CoA carboxylase; AMPK, AMP-activated protein kinase; DAG, diacylglycerol; FFA, free fatty acid; IRS1, insulin receptor substrate 1; PI 3-kinase, phosphatidylinositol 3-kinase; PGC-1, PPAR
Both pharmacological intervention (i.e., thiazolidinediones [TZDs]) and lifestyle modification (i.e., exercise training) are clinically effective treatments for improving whole-body insulin sensitivity. However, the mechanism(s) by which these therapies reverse lipid-induced insulin resistance in skeletal muscle is unclear. We determined the effects of 4 weeks of rosiglitazone treatment and exercise training and their combined actions (rosiglitazone treatment and exercise training) on lipid and glucose metabolism in high-fat–fed rats. High-fat feeding resulted in decreased muscle insulin sensitivity, which was associated with increased rates of palmitate uptake and the accumulation of the fatty acid metabolites ceramide and diacylglycerol. Impairments in lipid metabolism were accompanied by defects in the Akt/AS160 signaling pathway. Exercise training, but not rosiglitazone treatment, reversed these impairments, resulting in improved insulin-stimulated glucose transport and increased rates of fatty acid oxidation in skeletal muscle. The improvements to glucose and lipid metabolism observed with exercise training were associated with increased AMP-activated protein kinase
This article has been cited by other articles:
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||